Strong Price Performance and Market Position
On 23 December 2025, Venus Remedies recorded an intraday high of Rs.840, representing a 3.63% rise during the trading session. The stock has been on a positive trajectory for the past three consecutive days, delivering a cumulative return of 7.4% over this period. This recent price action outpaced the Pharmaceuticals & Biotechnology sector by 0.39% and the Sensex benchmark, which showed a decline of 0.18% on the same day.
Venus Remedies is currently trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a robust upward momentum. The stock’s intraday volatility was notably high at 93.26%, reflecting active trading interest and dynamic price movements throughout the session.
Long-Term Returns Surpass Market Benchmarks
Examining Venus Remedies’ performance over extended periods reveals a consistent pattern of market outperformance. Over the last one year, the stock generated returns of 165.49%, significantly exceeding the Sensex’s 8.76% return. Year-to-date figures show a similar trend, with Venus Remedies delivering 158.62% compared to the Sensex’s 9.31%.
Longer-term data further highlights the company’s strong market presence. Over three years, Venus Remedies posted a return of 361.00%, while the Sensex recorded 42.73%. The five-year and ten-year returns stand at 499.52% and 509.61%, respectively, compared to the Sensex’s 83.91% and 230.43% over the same periods. These figures illustrate the company’s ability to sustain growth and value creation over time.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Financial Strength and Profitability Metrics
Venus Remedies’ financial results over recent quarters have demonstrated notable growth in profitability. The company’s net profit for the latest six months stood at Rs.29.73 crores, reflecting a growth of 528.54%. Earnings before tax (excluding other income) for the quarter reached Rs.24.78 crores, showing an increase of 2073.68%. These figures indicate a strong earnings momentum and operational efficiency.
The company’s return on capital employed (ROCE) for the half-year period was recorded at 13.99%, marking its highest level. Return on equity (ROE) is at 10.5%, which, combined with a price-to-book value of 1.8, suggests an attractive valuation relative to its peers. Venus Remedies maintains a low average debt-to-equity ratio of zero, underscoring a conservative capital structure and limited reliance on external borrowings.
Consistent Quarterly Performance
Venus Remedies has declared positive results for four consecutive quarters, reinforcing its steady financial trajectory. The company’s growth in net profit by 473.5% in the September 2025 quarter further highlights its ability to generate value consistently. This sustained performance has contributed to the stock’s upward price movement and its current all-time high.
Comparative Market Performance
When compared to the broader market, Venus Remedies has outperformed the BSE500 index across multiple time frames. The stock’s returns over the last three months, one year, and three years have all exceeded the benchmark, reflecting its relative strength within the Pharmaceuticals & Biotechnology sector and the wider market.
Venus Remedies caught your attention? Explore our comprehensive research report with in-depth analysis of this micro-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth micro-cap analysis
- - Valuation assessment included
Volatility and Trading Dynamics
Today’s trading session for Venus Remedies was marked by high volatility, with an intraday volatility measure of 93.26%. This level of price fluctuation indicates active market participation and reflects the dynamic nature of the stock’s trading environment. Despite this, the stock maintained its upward trend and closed with a gain of 0.55%, contrasting with the Sensex’s decline of 0.18% on the same day.
Market Capitalisation and Sector Placement
Venus Remedies operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation and growth potential. The company’s market capitalisation grade is rated at 4, indicating a mid-cap status that balances growth opportunities with established market presence. This positioning has allowed Venus Remedies to capitalise on sectoral trends while maintaining a solid financial foundation.
Shareholding and Institutional Interest
Despite the company’s size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence of institutional ownership may reflect a cautious stance or differing perspectives on valuation and business fundamentals. Domestic mutual funds typically conduct detailed research on companies, and their limited exposure to Venus Remedies is a notable aspect of the stock’s ownership structure.
Summary of Key Metrics
To summarise, Venus Remedies’ recent performance is characterised by:
- All-time high stock price of Rs.840
- Outperformance of sector and Sensex indices across multiple time frames
- Strong profitability growth with net profit and PBT increases exceeding 500% and 2000% respectively
- High return on capital employed and return on equity
- Trading above all major moving averages
- Low debt-to-equity ratio indicating financial prudence
These factors collectively illustrate the company’s strong market position and financial health, culminating in the recent milestone of reaching its highest-ever stock price.
Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Claim Your Free Year →
